Skip To Main Content
Tarani Kanta Barman on Muck Rack

Tarani Kanta Barman

As seen in: Frontiers, MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tarani Kanta

Contact Tarani Kanta, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A phosphodiesterase-4 inhibitor reduces lung inflammation and fibrosis in a hamster model of SARS-CoV-2 infection

|
By Avijit Dutta, Debashis Dutta, Tarani Kanta Barman
| Frontiers
Introduction Coronavirus disease-2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a major global health concern that affected about 770.5 million people and caused 6.9 million deaths worldwide by September 11, 2023 (1).
Open in Who Shared Issue with article?

ADME, Pharmacokinetic Scaling, Pharmacodynamic and Prediction of Human Dose and Regimen of Novel Antiviral Drugs

|
By Tridib Chaira, Tarani Kanta Barman, Chandru Subramani, Tarani Kanta
| MDPI
Abstract : The search for new drugs is an extremely time-consuming and expensive endeavour. Much of that time and money go into generating predictive human pharmacokinetic profiles from preclinical efficacy and safety animal data. These pharmacokinetic profiles are used to prioritize or minimize the attrition at later stages of the drug discovery process.
Open in Who Shared Issue with article?

DS86760016, a Leucyl-tRNA Synthetase Inhibitor with Activity against Pseudomonas aeruginosa

|
By Manoj Kumar, Madhvi Rao, Kedar P. Purnapatre, Tarani Kanta Barman
| asm.org
Experimental Therapeutics Manoj Kumar, Madhvi Rao, Kedar P. Purnapatre, Tarani Kanta Barman, Vattan Joshi, Amuliya Kashyap, Tridib Chaira, Ramesh B. Bambal, Manisha Pandya, Souhaila Al Khodor, Dilip J. Upadhyay, Nobuhisa Masuda DOI: 10.1128/AAC.02122-18 ABSTRACT DS86760016 is a new leucyl-tRNA-synthetase inhibitor at the preclinical development stage.
Open in Who Shared Issue with article?
See all 4 articles